Ethionamide adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{Ethionamide}} {{CMG}} ; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRECATOR (ETHIONAMIDE) TABLET, FILM CO...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
(2 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Ethionamide}} | {{Ethionamide}} | ||
{{CMG}} ; | {{CMG}}; {{AE}} {{chetan}} | ||
==Adverse Reactions== | |||
===Gastrointestinal=== | |||
The most common side effects of ethionamide are gastrointestinal disturbances including [[nausea]], [[vomiting]], [[diarrhea]], abdominal pain, excessive salivation, metallic taste, stomatitis, anorexia and weight loss. Adverse gastrointestinal effects appear to be dose related, with approximately 50% of patients unable to tolerate 1 gm as a single dose. Gastrointestinal effects may be minimized by decreasing dosage, by changing the time of drug administration, or by the concurrent administration of an antiemetic agent. | |||
===Nervous System=== | |||
Psychotic disturbances (including mental depression), drowsiness, dizziness, restlessness, headache, and postural hypotension have been reported with ethionamide. Rare reports of peripheral neuritis, optic neuritis, diplopia, blurred vision, and a pellagra-like syndrome also have been reported. Concurrent administration of [[pyridoxine]] has been recommended to prevent or relieve neurotoxic effects. | |||
===Hepatic=== | |||
Transient increases in serum [[bilirubin]], [[SGOT]], [[SGPT]]. [[Hepatitis]] (with or without [[jaundice]]). | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d | publisher = | date = | accessdate }}</ref> | ===Other=== | ||
Hypersensitivity reactions including [[rash]], [[photosensitivity]], [[thrombocytopenia]] and [[purpura]] have been reported rarely. [[Hypoglycemia]], [[hypothyroidism]], [[gynecomastia]], [[impotence]], and [[acne]] also have occurred. The management of patients with diabetes mellitus may become more difficult in those receiving ethionamide.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d | publisher = | date = | accessdate }}</ref> | |||
==References== | ==References== |
Latest revision as of 03:00, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Adverse Reactions
Gastrointestinal
The most common side effects of ethionamide are gastrointestinal disturbances including nausea, vomiting, diarrhea, abdominal pain, excessive salivation, metallic taste, stomatitis, anorexia and weight loss. Adverse gastrointestinal effects appear to be dose related, with approximately 50% of patients unable to tolerate 1 gm as a single dose. Gastrointestinal effects may be minimized by decreasing dosage, by changing the time of drug administration, or by the concurrent administration of an antiemetic agent.
Nervous System
Psychotic disturbances (including mental depression), drowsiness, dizziness, restlessness, headache, and postural hypotension have been reported with ethionamide. Rare reports of peripheral neuritis, optic neuritis, diplopia, blurred vision, and a pellagra-like syndrome also have been reported. Concurrent administration of pyridoxine has been recommended to prevent or relieve neurotoxic effects.
Hepatic
Transient increases in serum bilirubin, SGOT, SGPT. Hepatitis (with or without jaundice).
Other
Hypersensitivity reactions including rash, photosensitivity, thrombocytopenia and purpura have been reported rarely. Hypoglycemia, hypothyroidism, gynecomastia, impotence, and acne also have occurred. The management of patients with diabetes mellitus may become more difficult in those receiving ethionamide.[1]
References
- ↑ "TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.